Hu14 Immunotherapy for High-Risk Neuroblastoma in Children
Part of Cancer clinical trials.
This study tests a new antibody-based immunotherapy called hu14 for children and young adults with high-risk neuroblastoma (an aggressive childhood cancer that has spread). The treatment is designed to help the immune system fight cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 months to under 18 years old at the time you join the study
- Diagnosed with high-risk neuroblastoma that has spread to other parts of the body
- Cancer can be seen on imaging scans (measurable disease)
- Good enough overall health to tolerate treatment (performance status score of 50 or higher)
- Organ function (heart, lungs, kidneys, liver, bone marrow) must be adequate based on recent blood tests and imaging
- Recovery from side effects of any previous chemotherapy treatments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (dinutuximab-beta plus chemotherapy) for children and young adults with newly diagnosed high-risk neuroblastoma. The goal is to see if adding this targeted therapy to standard chemo improves outcomes.
This Phase 3 study tests treatment strategies for children with high-risk neuroblastoma, aiming to improve how well the cancer responds and how long patients can stay in control. It compares different intensities and add-ons at key treatment steps depending on your child’s response and health.
This Phase 1 trial tests a combination of dinutuximab beta (an immunotherapy) and chemotherapy in children with high-risk neuroblastoma that did not respond to standard treatment or has come back or progressed. It aims to see how well the treatment works and how safely it can be given in this situation.
This study tests whether giving fewer chemotherapy drugs along with other targeted therapies (monoclonal antibodies) works well for children with high-risk neuroblastoma. It aims to reduce side effects while still treating the cancer effectively.
This trial tests adding a new drug called N-803 to a standard chemo-immunotherapy combination for children and young adults with high-risk neuroblastoma that has come back or not responded to previous treatments. The goal is to see if this combination works better at fighting the cancer.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
Hear when a new High-Risk Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.